Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Immunocore Announces Appointment of Eva-Lotta Allan to the Board

Published: Thursday, May 02, 2013
Last Updated: Thursday, May 02, 2013
Bookmark and Share
New position will strengthen management team as company expands operations.

Immunocore Limited announced the appointment of Eva-Lotta Allan to the Board as Chief Business Officer. This is a new position, which has been created to strengthen the company’s management team as Immunocore continues to expand its operations. Ms Allan will join Immunocore on 7 May 2013.

Immunocore has created a world-leading T cell receptor technology which exploits the power of the body’s own immune system to find and kill diseased cells. The company is developing a portfolio of products from the platform, called ImmTACs, for the treatment of cancer, chronic infectious disease and diabetes. The most advanced ImmTAC drug, IMCgp100 for the treatment of melanoma, is currently in clinical trials in the UK and USA.

Eva-Lotta Allan brings over two decades of business development experience from the biotechnology and life science industry and joins from Ablynx NV, where she served as Chief Business Officer since 2006. She was a key contributor to Ablynx’s transformation from a small private platform company to a significant public biotechnology company with an impressive pipeline and partnerships. In her role as Ablynx’s CBO, she closed a number of deals of significant value, with premier pharmaceutical companies bringing in over €160 million in non-dilutive cash to the company. Prior to Ablynx, Ms Allan was Senior Director of Business Development and Site Operations (Europe) at Vertex Pharmaceuticals. She received her degree in microbiology from the University of Stockholm.

James Noble, Immunocore’s Chief Executive Officer, said: “I am pleased to welcome Eva-Lotta to our senior Management team and Board of Directors at this critical point for Immunocore as we expand and develop our pipeline of products. She brings with her a wealth of knowledge and experience in business development.”

Eva-Lotta Allan commented on her appointment: “I am delighted to be joining Immunocore at this exciting time. I have been impressed by the quality of the science and unique and broad application of ImmTACs in cancer. I look forward to working with the Immunocore team and to establishing strategically important collaborations.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Immunocore Appoints Dr Eliot Forster as Chief Executive Officer
Immunocore Limited has announced the appointment of Dr Eliot Forster as Chief Executive Officer with immediate effect.
Monday, January 12, 2015
Immunocore and MedImmune Win the SCRIP Award
Immunocore and MedImmune are working together to generate ImmTACs against selected cancer targets.
Thursday, December 11, 2014
Immunocore and Lilly Enter Immunotherapy Agreement
Agreement to co-discover and co-develop novel cancer therapies.
Thursday, July 17, 2014
Immunocore Announces Re-organization of its Executive Management to Support Business Growth
Re-organization to support the continuing growth of Immunocore and Adaptimmune.
Thursday, March 27, 2014
Immunocore to Present at 32nd Annual JP Morgan Healthcare Conference
Company to provide an update on lead programme for melanoma.
Thursday, January 16, 2014
Immunocore and MedImmune Enter Immunotherapy Agreement
Companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.
Wednesday, January 08, 2014
Immunocore Appoints New Chairman of the Board
Dr Jonathan Knowles appointed as Company’s new executive Chairman of the Board of Directors.
Monday, November 18, 2013
Immunocore Appoints Chairman
Immunocore Limited announced the appointment of Dr Jonathan Knowles as the new executive Chairman of the Board of Directors with immediate effect.
Thursday, November 14, 2013
Immunocore Achieves Research Milestone in GSK Collaboration
Under the agreement announced in July, Immunocore will receive up to £142 million in pre-clinical milestone payments across the targets.
Thursday, November 07, 2013
Immunocore Initiates Phase IIa Clinical Trial for IMCgp100 in Melanoma
IMCgp100 for has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed.
Monday, November 04, 2013
Immunocore Initiates Phase IIa Clinical Trial for IMCgp100 in Melanoma
Phase IIa study to optimize the dosing regimen and maximize the efficacy of IMCgp100.
Thursday, October 31, 2013
Immunocore Named One of Fierce 15 Leading Biotechs of 2013
Immunocore ranked among the top private biotech firms globally.
Thursday, September 26, 2013
Immunocore Signs Research and Licensing Agreement with GlaxoSmithKline
Companies collaborate to discover ImmTACs against novel targets.
Tuesday, July 09, 2013
Immunocore and Genentech Enter Strategic Alliance
Licensing agreement to develop ImmTACs for multiple cancer targets.
Thursday, June 27, 2013
Revolutionary New Cancer Targeting Technology Described in Nature Medicine
Immunocore scientists manage to overcome cancer problem by boosting the ability of cancer-specific TCRs.
Monday, May 07, 2012
Scientific News
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
AACC 2016 Sees Clinical Chemistry Labs Drive Precision Medicine Offerings
Biomarker assays to enable precision medicine and risk assessment, mass spec-based tests designed for use in clinical labs large and small, and liquid biopsy technology captured the spotlight at the AACC annual meeting.
Automated Patch Clamping Trends
Learn more about current practices, preferences and metrics in ion channel drug screening using APC technology.
Lab-on-a-Stick: Miniaturised Clinical Testing For Fast Detection Of Antibiotic Resistance
A portable power-free test for the rapid detection of bacterial resistance to antibiotics has been developed by academics at Loughborough University and the University of Reading.
Genetic Ancestry of Cultivated Strawberry Unravelled
UNH scientists constructed a linkage map of the seven chromosomes of the diploid Fragaria iinumae, which allows them to fill in a piece of the genetic puzzle about the eight sets of chromosomes of the cultivated strawberry.
Progress In Vaccination Against Vespid Venom
Researchers at the Helmholtz Zentrum München and the Technical University Munich have presented a method which facilitates a personalised procedure for wasp allergy sufferers.
New Drug Target for Inflammatory Disorders
Penn study finds enigmatic molecules maintain equilibrium between fighting infection and inflammatory havoc.
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Mechanisms of Calcium Blockers
Researchers describe how the fundamental mode of action of two distinct chemical classes of calcium channel blockers differs.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!